866-997-4948(US-Canada Toll Free)

Mycosis Fungoides - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 65 Pages


Global Markets Directs, \'Mycosis Fungoides Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Mycosis Fungoides Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Mycosis Fungoides.
  • A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Mycosis Fungoides.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Mycosis Fungoides pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mycosis Fungoides Overview 6
Therapeutics Development 7
Pipeline Products for Mycosis Fungoides - Overview 7
Pipeline Products for Mycosis Fungoides - Comparative Analysis 8
Mycosis Fungoides - Therapeutics under Development by Companies 9
Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes 10
Mycosis Fungoides - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Mycosis Fungoides - Products under Development by Companies 13
Mycosis Fungoides - Products under Investigation by Universities/Institutes 14
Mycosis Fungoides - Companies Involved in Therapeutics Development 15
Shionogi & Co., Ltd. 15
Seattle Genetics, Inc. 16
Echo Therapeutics, Inc. 17
Mycosis Fungoides - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Assessment by Therapeutic Class 29
Drug Profiles 31
interferon gamma-1a - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
brentuximab vedotin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
brentuximab vedotin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
methotrexate-AzoneTS - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Genetically Modified T Cells-1138 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CIGB-128 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Mycosis Fungoides - Recent Pipeline Updates 46
Mycosis Fungoides - Product Development Milestones 61
Featured News & Press Releases 61
Nov 18, 2013: Actelion launches VALCHLOR gel 0.016% in the US 61
Jan 30, 2013: Ceptaris Announces Publication In JAMA Dermatology Of Positive Clinical Results For Mechlorethamine Gel In Early Stage Mycosis Fungoides 61
Nov 26, 2012: Seattle Genetics Receives FDA Orphan Drug Designation For Adcetris To Treat Mycosis Fungoides 62
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 63
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel\'s Gel Formulation Of Mechlorethamine Hydrochloride 63

Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Table


Number of Products under Development for Mycosis Fungoides, H2 2013 7
Number of Products under Development for Mycosis Fungoides - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Mycosis Fungoides - Pipeline by Shionogi & Co., Ltd., H2 2013 15
Mycosis Fungoides - Pipeline by Seattle Genetics, Inc., H2 2013 16
Mycosis Fungoides - Pipeline by Echo Therapeutics, Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 24
Number of Products by Stage and Route of Administration, H2 2013 26
Number of Products by Stage and Molecule Type, H2 2013 28
Number of Products by Stage and Therapeutic Class, H2 2013 30
Mycosis Fungoides Therapeutics - Recent Pipeline Updates, H2 2013 46

List of Chart


Number of Products under Development for Mycosis Fungoides, H2 2013 7
Number of Products under Development for Mycosis Fungoides - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 25
Number of Products by Stage and Top 10 Route of Administration, H2 2013 26
Number of Products by Top 10 Molecule Type, H2 2013 27
Number of Products by Stage and Top 10 Molecule Type, H2 2013 28
Number of Products by Top 10 Therapeutic Class, H2 2013 29
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *